Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Ligand Pharmaceuticals Incorporated (LGND - Snapshot Report) recently entered into a worldwide development and commercialization agreement with CURx Pharmaceuticals, Inc. for the former’s Captisol-enabled topiramate injection. The candidate will be developed for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epileptics who cannot take the oral form of topiramate.

Under this deal, Ligand could receive more than $21 million on the achievement of milestones and will receive royalties of 6% to 7.5% on future sales.

Currently, topiramate is only available in the oral form and is marketed as Topamax by Janssen Pharmaceuticals, Inc. Captisol-enabled topiramate injection was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) in Jul 2013. CURx intends to commence a phase II study next year.

We note that Ligand has been significantly involved in collaboration activities in 2013.

Ligand signed a major deal in Mar 2013 by entering into an agreement with Spectrum Pharmaceuticals, Inc. (SPPI - Snapshot Report). Following the deal, Spectrum Pharma acquired global development and commercialization rights to Ligand’s Captisol-enabled, propylene glycol-free (PG-free) melphalan. Captisol-enabled melphalan is currently being developed as a conditioning treatment before autologous stem cell transplant for patients suffering from multiple myeloma.

Ligand will receive a license fee, milestone payments and royalties from Spectrum Pharma following the potential commercialization of the candidate. Spectrum Pharma is now responsible for the ongoing pivotal clinical study on the candidate.

Continuing with its collaboration spree, Ligand joined forces with Azure Biotech for the development of a novel formulation of lasofoxifene in Jul 2013. This novel formulation targets an underserved market in the field of women's health.

Under this deal, Ligand will receive $2.7 million on the achievement of future development and regulatory milestones. Further royalty payments of 5% on future net sales will also be paid to Ligand.

Currently, Ligand carries a Zacks Rank #3 (Hold). Companies which look attractive include Biogen Idec Inc. (BIIB - Analyst Report) and Actelion Ltd. (ALIOF) with a Zacks Rank #1 (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E-HOUSE CHIN EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTL CONS AI ICAGY 33.30 +5.38%